NewcelX wins Brazil patent for NCEL-101 Type 1 diabetes manufacturing process through 2036

PUBT · 2d ago
NewcelX wins Brazil patent for NCEL-101 Type 1 diabetes manufacturing process through 2036
  • NewcelX received a Brazil patent covering the cell selection and enrichment manufacturing process for its lead type 1 diabetes program, NCEL-101.
  • Patent BR 112018010946-0 extends protection for the process until November 2036, strengthening the company’s global intellectual property position.
  • The update follows a successful FDA Type B Pre-IND meeting for NCEL-101 in combination with Eledon’s anti-CD40L antibody tegoprubart, supporting a path to clinical trials.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief on July 15, 2026, and is solely responsible for the information contained therein.